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these stents have not been well evaluated.
METHODS We performed additional analysis using data of the Ran-
domized Evaluation of Sirolimus-Eluting Stent Versus Everolimus-
Eluting Stent Trial (RESET trial). In this all-comer prospective multi-
center randomized open-label trial, 3196 patients were randomly
assigned to implant either SES (1600 patients) or EES (1596 patients).
Excluding the lesions where operators failed to implant assigned
stents and which we could not follow for 3 years, we included in
analysis 1666 lesions treated with SES and 1679 lesions with EES.
Primary endpoint of this study was target lesion revascularization
(TLR) within 3 years after index procedure. We detected the inde-
pendent predictors of TLR for each stents using multivariate logistic
regression model instead of Cox’s proportional hazard model because
log minus log curve of any predictor did not prove linearity of hazard
during follow-up. We also analyzed angiographic data of some pa-
tients participating QCA substudy in RESET trial, stratifying important
predictors.
RESULTS In RESET trial, there was no signiﬁcant difference in target
lesion revascularization between the SES and EES groups (7.9% versus
6.6%; P¼0.16). After adjustment for the clinical factors of p<0.1 in
univariate analyses, the following factors were independent pre-
dictors of TLR. In SES group, hemodialysis (odds ratio [OR], 6.36; 95%
conﬁdence interval [CI], 3.17-12.61: p<0.0001) and lowered ejection
fraction <30% (OR, 2.94; 95% CI, 1.06-7.54: p¼0.04) were an inde-
pendent predictor of TLR. On the other hand, in EES group, although
prior PCI (OR, 2.16; 95% CI, 1.37-3.45: p¼0.001), number of stents more
than 2 (OR, 2.14; 95% CI, 1.16-4.06: p¼0.02), ostium lesion (OR, 0.40;
95% CI, 0.14-0.93: p¼0.03), and direct stenting (OR, 0.56; 95% CI, 0.31-
0.97: p¼0.04) were also independent predictors of TLR, hemodialysis
was a strong independent predictor of TLR (OR, 2.70; 95% CI, 1.37-5.11:
p¼0.005). In QCA data, late loss in 8 months follow-up coronary
angiogram were similar after SES or EES implantation in both all
cohort and stratiﬁed groups with hemodialysis or diabetes.
CONCLUSIONS In general, the clinical factors of TLR between SES
and EES were similar. Hemodialysis was a strong clinical predictor of
TLR in both stents.
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BACKGROUND The duration of dual antiplatelet therapy (DAPT) after
Everolimus-eluting stent (EES) implantation is controversial. Short
term of DAPT was recommended, but long term of DAPT has been
reported to be effective. We studied about major adverse cardiac and
cerebral events (MACCE: combined end point of all cause of death,
nonfatal myocardial infarction and cerebral arterial disorder) over the
patients who were free from MACCE during the ﬁrst two years after
EES implantation.
METHODS A total of 1918 patients who underwent successful percu-
taneous coronary intervention (PCI) with EES at 22 centers in Japan
from 2010 through 2011 were enrolled, and 742 patients were followed
over 2 years free from MACCE. We divided these MACCE-free patients
into two groups: those who were prescribed DAPT over 2 years (Over-
2-Year DAPT: n¼591) and those who were not (Under-2-Year DAPT:
n¼151). We compared these two groups about MACCE after 2-year
follow-up with and without baseline adjustment by propensity score
matching (n¼145 in both group). And we studied about bleeding, stent
thrombosis and restenosis.
RESULTS A total of 50 MACCE were observed in this study (Over-2-
Year DAPT, 38; Under-2-Year DAPT, 12, respectively) without signiﬁ-
cant difference (Log-rank test, p¼0.19). Even after baseline adjust-
ment, there were no difference about MACCE (over-2-Year DAPT, 8;
Under-2-Year DAPT, 11, respectively, p¼0.19). In this study, 15 of
major bleeding, 5 of restenosis and 2 of stent thrombosis were
observed after 2-year follow-up, and there were no statistical differ-
ence, although the events numbers were not enough to compare.CONCLUSIONS Continuing DAPT did not prevent MACCE in patients
who were free from MACCE during the ﬁrst two years after ever-
olimus-eluting stent implantation.
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BACKGROUND A patient-level meta-analysis of 5 randomized trials
including 4,896 patients found that the XIENCE cobalt chromium
everolimus drug-eluting stent (DES) signiﬁcantly improved cardio-
vascular (CV) outcomes compared with bare metal stents (BMS) (Val-
gimigli et al., 2014). Using these results, a cost-effectiveness analysis
(CEA) was conducted comparing XIENCE vs. BMS in percutaneous
coronary intervention (PCI).
METHODS The CEA was conducted using a Markov state transition
model with a 2-year time horizon from the U.S. payer perspective. The
base case evaluated lesion-speciﬁc outcomes including CV-related
mortality, target vessel revascularization (TVR), TVR-related
myocardial infarction (MI), and stent thrombosis (ST). Patient-ori-
ented outcomes were evaluated in a one-way sensitivity analysis with
all-cause mortality, TVR, all-cause MI, and ST. Transition probabilities
and risk of clinical events were taken from the Valgimigli 2014 meta-
analysis. Resource use and unit costs (2015 USD) from the published
literature were included for index PCI with XIENCE or BMS, TVR,
MI, and dual antiplatelet therapy (DAPT). Quality of life impacts (i.e.,
health utilities) from the published literature were included for cor-
onary artery disease (CAD), MI, and TVR.
RESULTS The lesion-speciﬁc base-case analysis found that XIENCE
was more effective and less costly than BMS, resulting in an additional
0.018 quality-adjusted life years (QALYs) and a cost savings of $236
per patient. The patient-oriented sensitivity analysis provided similar
results that XIENCE was more effective and less costly than BMS,
resulting in an additional 0.013 QALYs and a cost savings of $288 per
patient. Results were robust to the majority of sensitivity analyses,
only being sensitive to pricing for clopidogrel ($9,755 per QALY). The
probabilistic sensitivity analysis predicted that XIENCE was associ-
ated with a 99.5% chance of being cost saving or cost-effective vs.
BMS at a cost per QALY threshold of $50,000.
CONCLUSIONS Previous studies assessing cost-effectiveness of DES
vs. BMS have shown mixed results which may be due to the clinical
performance of earlier generation DES. Utilizing data from a high-
quality, patient-level meta-analysis, our study clearly demonstrated
that XIENCE is an economically attractive strategy compared to BMS
for PCI.
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BACKGROUND TARGET I randomized controlled trial (RCT) aimed to
compare the safety and effectiveness of an abluminal groove-ﬁlled
biodegradable polymer sirolimus-eluting stent (FIREHAWK, Micro-
Port Medical, Shanghai, China) with a cobalt-chromium everolimus-
eluting stent (CoCr-EES) XIENCE V for the treatment of single de novo
Table. Clinical Outcomes Through 4 Years
0w1 Year 1w4 Year(s) 0w4 Years
FIREHAWK
n[227
CoCr-EES
n[231 Log-rank p
FIREHAWK
n[226
CoCr-EES
n[229 Log-rank p
FIREHAWK
n[227
CoCr-EES
n[231 Log-rank p
TLF, % (n) 2.2 (5) 2.2 (5) 0.98 2.2 (5) 4.0 (9) 0.30 4.4 (10) 6.1 (14) 0.43
PoCE, % (n) 3.5 (8) 7.3 (17) 0.07 5.8 (13) 7.9 (18) 0.38 9.2 (21) 15.1 (35) 0.053
Death, % (n) 0.4 (1) 0.9 (2) 0.57 1.8 (4) 1.7 (4) 0.99 2.2 (5) 2.6 (6) 0.78
Cardiac Death, % (n) 0.4 (1) 0 (0) 0.32 0.4 (1) 0.4 (1) 0.99 0.9 (2) 0.4 (1) 0.56
MI, % (n) 1.3 (3) 2.2 (5) 0.49 0 (0) 1.3 (3) 0.08 1.3 (3) 3.5 (8) 0.14
Q Wave MI 0 (0) 0 (0) N/A 0 (0) 0.4 (1) 0.32 0 (0) 0.4 (1) 0.32
Non Q Wave MI 1.3 (3) 2.2 (5) 0.49 0 (0) 0.9 (2) 0.16 1.3 (3) 3.1 (7) 0.21
TV-MI 1.3 (3) 1.7 (4) 0.72 0 (0) 0.9 (2) 0.16 1.3 (3) 2.6 (6) 0.33
Any Revascularization, % (n) 1.8 (4) 4.8 (11) 0.07 4.5 (10) 6.2 (14) 0.43 6.2 (14) 11.0 (25) 0.07
iTLR, % (n) 0.4 (1) 0.4 (1) 0.99 1.8 (4) 3.5 (8) 0.16 2.2 (5) 4.0 (9) 0.33
Deﬁnite/Probable ST, % (n) 0 (0) 0 (0) N/A 0 (0) 0.4 (1) 0.32 0 (0) 0.4 (1) 0.32
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outcomes.
METHODS A total of 458 patients (vessel size between 2.25w4.0mm
and lesion length  24mm) were enrolled in the TARGET I RCT. The
primary non-inferiority endpoint was in-stent late lumen loss (LLL) at
9 months. Secondary endpoints were target lesion failure (TLF), a
composite of cardiac death, target vessel myocardial infarction (TV-
MI), or ischemia-driven target lesion revascularization (iTLR), and
patient-oriented composite endpoint (PoCE), a composite of all death,
all MI, or any repeat revascularization. Clinical follow-up (f/u) was
scheduled at 1 month, 6 and 12 months, and annually up to 5 years for
all enrolled patients. All adverse clinical events were adjudicated by
an independent committee.
RESULTS Previous reports have demonstrated FIREHAWK stent was
non-inferior to CoCr-EES for the primary endpoint of 9-month in-stent
LLL (0.130.24 mm vs. 0.130.18 mm, p for non-inferiority <0.0001),
and the two groups had similar clinical outcomes at 1 year. 445 (97.2%)
patients completed 4-year clinical f/u. There were still no signiﬁcant
differences between groups up to 4 years in terms of any composite
endpoints or individual components (Table). However, a landmark
analysis at 1 year showed non-signiﬁcant trends of lower incidences of
MI (0% vs. 1.3%, log-rank p¼0.08) and iTLR (1.8% vs. 3.5%, log-rank
p¼0.16) in favoring FIREHAWK group between 1 year and 4 years.
Furthermore, the 4-year rate of PoCE was 9.2% in FIREHAWK group
and 15.1% in CoCr-EES group, respectively, with a borderline differ-
ence (log-rank p¼0.053). No deﬁnite/probable stent thrombosis (ST)
was documented in FIREHAWK group through 4 years.
CONCLUSIONS In TARGET I RCT, the 4-year f/u results conﬁrmed
that the novel FIREHAWK stent had a durable safety and efﬁcacy
proﬁle, which was comparable to the best-in-class CoCr-EES in single
de novo coronary lesions. (ClinicalTrials.gov Identiﬁer: NCT01196819)
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BACKGROUND A non-inferiority study evaluating the long-term
safety and effectiveness of the Elixir DESyne BD Novolimus Eluting
Coronary Stent System (NECSS), a Co-Cr stent with a biodegradablepolymer compared to the control Endeavor Zotarolimus Eluting Cor-
onary Stent System (ZECSS) (Medtronic, Santa Rosa, CA).
METHODS 149 patients were randomized 3:1, either to the DESyne BD
NECSS or to the Endeavor ZECSS. Patients were analyzed for the pri-
mary endpoint (non-inferiority and superiority) of in-stent late lumen
loss (LLL) assessed by qualitative coronary angiography (QCA) at 6
months. Secondary endpoints were evaluated at 1, 6, 9, and 12 months
and annually through 5 years, and included a device-orientated
composite endpoint (DoCE) deﬁned as: cardiac death, target vessel
MI, clinically-indicated target lesion revascularization (TLR); clini-
cally-indicated target vessel revascularization (TVR); and stent
thrombosis. Lesions were also evaluated for 6-month angiographic
endpoints including: in-segment LLL, percent diameter stenosis,
post-procedure minimal lumen diameter, and angiographic binary
restenosis (ABR) (50%). A subset of patients underwent 6-month
intravascular ultrasound (IVUS) evaluation.
RESULTS The study met the primary endpoint demonstrating both
non-inferiority and superiority of the DESyne BD NECSS compared to
the control (0.120.15 vs 0.670.47, p<0.001). Six-month in-stent
ABR was signiﬁcantly lower for DESyne BD (0% vs 7.9%, p¼0.003).
Excellent clinical results were demonstrated for both devices with
sustained low clinical event rates observed through 36 months
(Table 1). Long-term clinical results through 48 months will be
presented.
CONCLUSIONS The DESyne BD NECSS demonstrated both non-infe-
riority and superiority over Endeavor for in-stent late lumen loss at 6
months. Clinical events remained low through 36 months; clinical
results through 48 months will be presented.
Table 1. Angiographic, IVUS and Clinical ResultsDESyne BD Endeavor p-valueAngiographic ResultsBaseline RVD (post-procedure) 3.00þ0.37 3.08þ0.35 0.21
6 month angiographic/IVUSIn-stent Late Lumen Loss 0.12þ0.15 0.67þ0.47 <0.001
% neointimal volume 3.6þ4.2 20.7þ14.2 <0.001
Clinical Results6-month DoCE (%) 2.7 3.2 1.00Clinically-indicated TLR 1.8 3.2 0.5212 month DoCE (%) 2.7 3.2 1.00Clinically-indicated TLR 1.8 3.2 1.5224 month DoCE (%) 2.7 3.2 1.00Clinically-indicated TLR 1.8 3.2 1.5236 month DoCE (%) 5.4 6.5 0.68Clinically-indicated TLR 2.7 6.5 0.30CATEGORIES CORONARY: Stents: Drug-Eluting
KEYWORDS Biodegradable polymer, DES, Novolimus
